Are Immune Checkpoint Inhibitors Safe and Effective in Lung Cancer Patients with Pre-Existing Interstitial Lung Disease?

References

• Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br. J. Cancer 91(Suppl. 2), S3–S10 (2004).
   PubMedGoogle Scholar
• Zhou F, Qiao M, Zhou C. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol. Immunol. 18(2), 279–293 (2021).
   PubMed Web of Science ®Google Scholar
• Ogura T, Takigawa N, Tomii K et al. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respir. Investig. 57(6), 512–533 (2019).
   PubMed Web of Science ®Google Scholar
• Tasaka Y, Honda T, Nishiyama N et al. Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small-cell lung cancer patients with interstitial lung disease. Lung Cancer 155, 120–126 (2021).
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Kaira K, Shinomiya S et al. Pre-existing interstitial lung disease does not affect prognosis in non-small-cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab. Thorac. Cancer 12(3), 304–313 (2021).
   PubMed Web of Science ®Google Scholar
• Takahara Y, Tanaka T, Ishige Y et al. Risk factors for acute exacerbation in lung cancer complicated by interstitial lung disease with slight reticular shadows [Article]. Thoracic. Cancer 12(20), 2758–2766 (2021).
   PubMed Web of Science ®Google Scholar
• Ikeda S, Kato T, Kenmotsu H et al. A Phase II study of atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonitis. J. Thorac. Oncol. 15(12), 1935–1942 (2020).
   PubMed Web of Science ®Google Scholar
• Kanai O, Kim YH, Demura Y et al. Efficacy and safety of nivolumab in non-small-cell lung cancer with pre-existing interstitial lung disease. Thorac. Cancer 9(7), 847–855 (2018).
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25(9), 603–605 (2010).
   PubMed Web of Science ®Google Scholar
• Mao S, Liu Y, Zhou F et al. Zhou Association of baseline pulmonary fibrosis with the outcome of PD-1 inhibitor in patients with advanced non-small-cell lung cancer. J. Thorac. Oncol. 14(10), S383 (2019).
   Web of Science ®Google Scholar
• Cho JY, Kim J, Lee JS et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small-cell lung cancer. Lung Cancer 125, 150–156 (2018).
   PubMed Web of Science ®Google Scholar
• Atchley WT, Alvarez C, Saxena-Beem S et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina. Chest 160(2), 731–742 (2021).
   PubMed Web of Science ®Google Scholar
• Fujimoto D, Morimoto T, Ito J et al. A pilot trial of nivolumab treatment for advanced non-small-cell lung cancer patients with mild idiopathic interstitial pneumonia. Lung Cancer 111, 1–5 (2017).
   PubMed Web of Science ®Google Scholar
• Fujimoto D, Yomota M, Sekine A et al. Nivolumab for advanced non-small-cell lung cancer patients with mild idiopathic interstitial pneumonia: a multicenter, open-label single-arm Phase II trial. Lung Cancer 134, 274–278 (2019).
   PubMed Web of Science ®Google Scholar
• Fukihara J, Sakamoto K, Koyama J et al. Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors. Clin. Lung Cancer 20(6), 442–450; e4 (2019).
   PubMed Web of Science ®Google Scholar
• Komiya K, Nakamura T, Abe T et al. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small-cell lung cancer. Thorac. Cancer 10(9), 1798–1804 (2019).
   PubMed Web of Science ®Google Scholar
• Shibaki R, Murakami S, Matsumoto Y et al. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small-cell lung cancer patients with pre-existing interstitial lung disease. Med. Oncol. 36(6), 49 (2019).
   PubMed Web of Science ®Google Scholar
• Byeon S, Cho JH, Jung HA et al. PD-1 inhibitors for non-small-cell lung cancer patients with special issues: real-world evidence. Cancer Med. 9(7), 2352–2362 (2020).
   PubMed Web of Science ®Google Scholar
• Fujita T, Kuroki T, Hayama N et al. Pembrolizumab for previously untreated patients with advanced non-small-cell lung cancer and pre-existing interstitial lung disease. Intern. Med. 59(16), 1939–1945 (2020).
   PubMed Web of Science ®Google Scholar
• Hata H, Mio T, Yamashita D et al. Factors associated with efficacy and nivolumab-related interstitial pneumonia in non-small-cell lung cancer: a retrospective survey. Cancer Control 27(4), 1073274820977200 (2020).
   Web of Science ®Google Scholar
• Nishiyama N, Honda T, Sema M et al. The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease. Int. J. Clin. Oncol. 25(2), 282–291 (2020).
   PubMed Web of Science ®Google Scholar
• Okada N, Matsuoka R, Sakurada T et al. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. Sci. Rep. 10(1), 13773 (2020).
   PubMed Web of Science ®Google Scholar
• Shibaki R, Murakami S, Matsumoto Y et al. Association of immune-related pneumonitis with the presence of pre-existing interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Cancer Immunol. Immunother. 69(1), 15–22 (2020).
   PubMed Web of Science ®Google Scholar
• Isono T, Kagiyama N, Takano K et al. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small-cell lung cancer treated with immune checkpoint inhibitors. Thorac. Cancer 12(2), 153–164 (2021).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Shimizu J, Hasegawa T et al. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis. BMC Cancer 21(1), 924 (2021).
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Nakanishi Y, Gemma A et al. Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: postmarketing surveillance. Cancer Sci. 112(11), 4692–4701 (2021).
   PubMed Web of Science ®Google Scholar
• Ichimura T, Hinata M, Ichikura D et al. Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case-control study. Cancer Chemother. Pharmacol. 89(1), 21–30 (2022).
   PubMed Web of Science ®Google Scholar
• Ikeda S, Kato T, Kenmotsu H et al. Atezolizumab for pretreated non-small-cell lung cancer with idiopathic interstitial pneumonia: final analysis of Phase II AMBITIOUS study. Oncologist 27(9), e720–e702 (2022).
   PubMed Web of Science ®Google Scholar
• Ohe Y, Yamazaki N, Yamamoto N et al. The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study. Jpn J. Clin. Oncol. 52(6), 623–632 (2022).
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Kamitani T, Kanda K et al. Real-world outcomes of pembrolizumab monotherapy in non-small-cell lung cancer in Japan: a post-marketing surveillance. Cancer Sci. 113(9), 3110–3119 (2022).
   PubMed Web of Science ®Google Scholar
• Sawa K, Sato I, Takeuchi M et al. Risk of pneumonitis in non-small-cell lung cancer patients with pre-existing interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study. Cancer Immunol. Immunother. 72(3), 591–598 (2023).
   PubMed Web of Science ®Google Scholar
• Xia L, Liu Y, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist 24(Suppl. 1), S31–S41 (2019).
   PubMedGoogle Scholar
• Yan YD, Zhao Y, Zhang C et al. Toxicity spectrum of immunotherapy in advanced lung cancer: a safety analysis from clinical trials and a pharmacovigilance system. EClinicalMedicine 50, 101535 (2022).
   PubMedGoogle Scholar
• Sears CR, Peikert T, Possick JD et al. Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. an official American Thoracic Society Research Statement. Am. J. Respir. Crit. Care Med. 200(6), e31–e43 (2019).
   PubMed Web of Science ®Google Scholar
• Gomatou G, Tzilas V, Kotteas E et al. Immune checkpoint inhibitor-related pneumonitis. Respiration 99(11), 932–942 (2020).
   PubMed Web of Science ®Google Scholar
• Suresh K, Voong KR, Shankar B et al. Pneumonitis in non-small-cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J. Thorac. Oncol. 13(12), 1930–1939 (2018).
   PubMed Web of Science ®Google Scholar
• Wang J, Zhou C, Yao W et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 23(6), 739–747 (2022).
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Cho BC, Ou X et al. Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: a Phase 1b, open-label, multicenter trial. J. Thorac. Oncol. 17(5), 718–723 (2022).
   PubMed Web of Science ®Google Scholar
• Sugano T, Seike M, Saito Y et al. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. Thorac. Cancer 11(4), 1052–1060 (2020).
   PubMed Web of Science ®Google Scholar
• Ueda T, Aokage K, Nishikawa H et al. Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung. J. Cancer Res. Clin. Oncol. 144(5), 835–844 (2018).
   PubMed Web of Science ®Google Scholar
• Daido W, Masuda T, Imano N et al. Pre-existing interstitial lung abnormalities are independent risk factors for interstitial lung disease during durvalumab treatment after chemoradiotherapy in patients with locally advanced non-small-cell lung cancer. Cancers (Basel) 14(24), 6236 (2022).
   PubMed Web of Science ®Google Scholar
• Kitagawa S, Hakozaki T, Kitadai R et al. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small-cell lung cancer: case series and literature review. Thorac. Cancer 11(7), 1927–1933 (2020).
   PubMed Web of Science ®Google Scholar
• Torasawa M, Yoshida T, Yagishita S et al. Nivolumab versus pembrolizumab in previously-treated advanced non-small-cell lung cancer patients: a propensity-matched real-world analysis. Lung Cancer 167, 49–57 (2022).
   PubMed Web of Science ®Google Scholar
• Zhang M, Fan Y, Nie L et al. Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small-cell lung cancer and pre-existing interstitial lung diseases: a systematic review and meta-analysis. Chest 161(6), 1675–1686 (2022).
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Shiroyama T, Kuge T et al. Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small-cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies. Transl. Lung Cancer Res. 11(9), 1835–1846 (2022).
   PubMedGoogle Scholar
• Suresh K, Psoter KJ, Voong KR et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J. Thorac. Oncol. 14(3), 494–502 (2019).
   PubMed Web of Science ®Google Scholar